
Diagnoly helps clinicians improve prenatal screening by providing real‑time AI analysis of fetal ultrasound to detect abnormalities and ensure complete exams. It builds Fetoly, a DeepTech B2B SaaS and medical device that uses AI and deep learning models integrated with ultrasound systems to provide on‑device, real‑time feedback during scans. Fetoly analyzes anatomical landmarks, detects over 100 fetal abnormalities, validates exam completeness against ISUOG guidelines, and automates repetitive measurements to increase consistency. The solution runs locally on mobile devices and remains compatible with major ultrasound platforms without requiring cloud services, preserving clinical data control. Diagnoly targets obstetricians and healthcare providers and holds FDA clearance for Fetoly‑Heart and CE marking for fetal heart and brain analysis.

Diagnoly helps clinicians improve prenatal screening by providing real‑time AI analysis of fetal ultrasound to detect abnormalities and ensure complete exams. It builds Fetoly, a DeepTech B2B SaaS and medical device that uses AI and deep learning models integrated with ultrasound systems to provide on‑device, real‑time feedback during scans. Fetoly analyzes anatomical landmarks, detects over 100 fetal abnormalities, validates exam completeness against ISUOG guidelines, and automates repetitive measurements to increase consistency. The solution runs locally on mobile devices and remains compatible with major ultrasound platforms without requiring cloud services, preserving clinical data control. Diagnoly targets obstetricians and healthcare providers and holds FDA clearance for Fetoly‑Heart and CE marking for fetal heart and brain analysis.
Product: Fetoly — on-device, real-time AI for fetal ultrasound (landmarking, QA, anomaly detection)
Regulatory: FDA clearance for Fetoly-Heart and CE marking for fetal heart and brain analysis
Founded: 2020 — Lyon, France
Latest funding: Seed round announced Apr 8, 2025 (€5.5M reported)
Prenatal fetal ultrasound quality assurance and anomaly detection
2020
Medical Equipment Manufacturing
€5.5M
Reported seed round announced Apr 8, 2025; participants include Mutuelles Impact, Newfund and existing investor BAdGE
Profiles list multiple prior funding events and non-equity assistance but details not specified in evidence
“Mutuelles Impact and Newfund participate as lead investors in the Seed round; additional investors reported across rounds include XAnge, Les Business Angels des Grandes Écoles, WorldUpstart, Angelor, MassChallenge Switzerland”
| Company |
|---|
Start-up activity
Diagnoly is redefining obstetric and maternal-fetal medicine through real-time AI in ultrasound. Our AI-powered medical software connects directly to ultrasound machines and secures fetal ultrasound examination. By processing the live ultrasound stream in real-time, our unique solution significantly reduces user dependency of fetal ultrasound and helps practitioners identify most cardiac and cerebral pathologies — without changing their existing workflow.
Now certified in the United States and Europe, our technology supports healthcare professionals in improving fetal screening. Our mission is to reduce the risk of lifelong disabilities, handicaps or lethal outcomes for the concerned babies.
Backed by top-tier VCs (XAnge and Newfund Capital), we offer a collaborative and entrepreneurial environment where each team member contributes to advancing medical innovation with a direct impact on patient outcomes.
Key Responsibilities
We are seeking a driven and ambitious Sales Representative for the US. This role is ideal for motivated, hands-on sales professionals who want to make a real impact in women’s health. You will play a key role in building Diagnoly’s presence in the US, particularly with large OB and MFM clinics, health systems and private practices.
Candidate Profile
Preferred
What we offer
If you are interested, do not hesitate to write to us on careers@diagnoly.com. Please provide your CV and a short motivation for this position in your mail.